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Abstract
Background
Using data from the SOX Trial, we recently developed a clinical prediction model for
occurrence of the post-thrombotic syndrome (PTS) after proximal deep vein thrombosis
(DVT), termed the SOX-PTS score. The score includes anatomical extent of DVT; body
mass index; and baseline Villalta score.

Objective
To externally validate the SOX-PTS score.

Methods
Logistic regression analysis of data from the ATTRACT Trial which evaluated
pharmacomechanical catheter directed thrombolysis in patients with proximal DVT. The
primary outcome was the occurrence of PTS (defined as Villalta score ≥ 5) from 6 to 24
months after DVT. Secondary outcomes included moderate-severe PTS (Villalta scale ≥ 10)
and severe PTS (Villalta scale ≥ 14). Predictive performance was assessed by discrimination
and calibration. An updated score was evaluated in an exploratory analysis.

Results
691 ATTRACT patients were included, of whom 328 (47%) developed PTS. The c-statistic
was 0.63; 95% confidence interval (CI) 0.59-0.67 for PTS. The model's performance
appeared to be better for the outcomes moderate to severe PTS and severe PTS (c-statistic
0.67; 95% CI 0.62 to 0.72 for moderate-severe PTS and 0.70; 0.64 to 0.77 for severe PTS).
An updated model with age as an additional variable performed similarly to the original
model.
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Conclusion
We externally validated the SOX-PTS score for estimating the risk of developing PTS,
moderate to severe PTS, and severe PTS, in patients with proximal DVT. The score may be
useful to predict PTS at the time of DVT diagnosis. Further external validation in different
patient cohorts is required.

Keywords: Deep Vein Thrombosis, Postthrombotic Syndrome, Clinical Prediction Rule,
Body Mass Index, Iliac Vein
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Introduction
The post-thrombotic syndrome (PTS) is a chronic complication of deep vein thrombosis
(DVT) that develops in up to 50% of patients despite optimal anticoagulation, usually
becoming established in the first two years after DVT [1. Manifestations range from mild leg
pain and discomfort to chronic non-healing leg ulcers. In order to inform patients with DVT
about their future outcome, improve their management, and optimally design studies of
preventive and treatment strategies, better prognostication of the individual patient's risk of
developing PTS is needed.

We recently developed the SOX-PTS score, a clinical prediction model for PTS that was
derived in a prospective cohort of patients with proximal DVT (SOX Trial participants) [2.
The score identified 3 independent predictors, namely anatomical extent of DVT (1 point for
iliac vein involvement); body mass index (BMI) (2 points for BMI ≥35 kg/m2); and baseline
Villalta score (1 point for ≥10; 2 points for ≥14), with a possible maximum score of 5, that
were combined into a model that predicted the risk for PTS development. However, this score
has not been externally validated in an independent sample. The aim of the current study was
to apply the SOX-PTS score to patients whose data were not used in model development,
quantify the model’s predictive performance, and update the model if needed.

Methods
Validation cohort
The validation cohort consisted of participants in the Acute Venous Thrombosis: Thrombus
Removal with Adjunctive Catheter-Directed Thrombolysis (ATTRACT) trial, a multicenter
randomized controlled trial of anticoagulation alone (control group) compared with
anticoagulation plus pharmacomechanical catheter-directed thrombolysis (PCDT), for the
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prevention of PTS. [3 Patients with symptomatic proximal DVT involving the femoral,
common femoral or iliac vein (with or without other involved ipsilateral veins) were enrolled
at 56 clinical centers in the United States (list of participating centers in Supporting
Information). Patients were excluded if they were younger than 16 or older than 75 years of
age, were pregnant, had symptoms for more than 14 days, were at high bleeding risk, had
active cancer, had established PTS, or had ipsilateral DVT in the previous 2 years. All the
patients provided written informed consent.

Patients in each treatment group received initial and long-term anticoagulant therapy, and
were provided sized-to-fit, knee-high, elastic compression stockings (30 to 40 mm Hg of
pressure) at the 10-day follow-up visit and every 6 months. [4 In the PCDT arm,
recombinant tissue plasminogen activator (rt-PA) was delivered via one of three methods, as
published previously. [3, 5

Outcome
The primary outcome of the ATTRACT trial was the development of PTS according to the
Villalta scale. The Villalta scale is a clinical measure for PTS that grades the severity of 5
patient-rated symptoms (pain, cramps, heaviness, pruritus, and paresthesia) and 6 clinicianrated clinical signs (edema, redness, skin induration, hyperpigmentation, venous ectasia, and
pain on calf compression) from 0 (absent) to 3 (severe). [6 A summative score of 5 or more
or an ulcer in the leg with the index DVT indicates the presence of the PTS. In ATTRACT,
these criteria had to be met at any time between the 6-month and the 24-month follow-up
visits for patients to be classified as having PTS.

Statistical analysis
5

All available data in the database were used to maximize the power and generalizability of
the results.

We assessed the predictive performance of the SOX-PTS score in the ATTRACT trial cohort
by examining measures of discrimination and calibration. Discrimination is the ability of the
risk score to differentiate between patients who do and do not experience an event during the
study period. This measure is quantified by calculating the c-statistic, the equivalent of the
receiver operating characteristic (ROC) based area under the curve, with a value of 0.5
representing chance and 1 representing perfect discrimination. Calibration refers to how
closely the predicted 24-month PTS rates using the SOX-PTS score agreed with the observed
24-month PTS rates. This was assessed by plotting observed proportions versus predicted
probabilities and by calculating the calibration slope. [7

Because the PTS outcome in the derivation cohort was defined using Ginsberg PTS criteria
[8, which are known to capture more severe PTS than Villalta PTS criteria [9, we planned a
pre-specified secondary analysis that assessed model performance with moderate-severe PTS
(Villalta score of 10-14) and severe PTS (Villalta score>14) as outcomes.

Handling of missing data
Multiple imputation was performed on patients in the ATTRACT cohort that had missing
outcome data (Villalta scores) assuming they were missing at random. Patients who missed
all four PTS assessments were included in the multiple imputation. In addition, missing PTS
assessments in patients who were lost to follow up before completing all four PTS
assessments were also imputed if all existing assessments had a Villalta score <5. Villalta
scores were imputed using available Villalta scores in the first 6 months and baseline
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covariates. We created 20 imputed datasets, with the missing values replaced by imputed
values drawn from their predicted distribution by using the observed data. Fully conditional
statement was chosen as the imputation method. In this method, the predictive mean
matching method is used for all continuous variables and the logistic regression method is
used for all classification variables. [10 No interaction terms were included in the
imputation model. Performance of the SOX-PTS score in the imputed ATTRACT dataset
was analyzed as a sensitivity analysis. The main analysis was performed on the non-imputed
original dataset.

Exploratory analysis- model updating
In exploring model updating, we considered the following baseline covariates from the
ATTRACT cohort: treatment arm, iliofemoral vs. femoral-popliteal DVT, sex, age, BMI,
DVT symptom duration, previous ipsilateral DVT, contralateral DVT, and inpatient or
outpatient status at the time of DVT diagnosis. Only statistically significant covariates (P
<0.05) in a multivariate logistic regression were used to construct a new risk score. The
discrimination and calibration of the new risk score were examined using the ATTRACT
data. A sensitivity analysis was conducted on the discrimination and calibration of the new
risk score using the imputed ATTRACT dataset. The above analyses were repeated for two
secondary outcomes: moderate to severe PTS, and severe PTS. Internal validation of the new
score was performed within the ATTRACT database using the bootstrapping technique.

All analyses were performed using SAS statistical software version 9.4 (SAS Institute Inc).

Results
From December 2009 through December 2014, 692 patients underwent randomization to the
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ATTRACT trial (337 to the PCDT group and 355 to the control group). One patient who was
assigned to the PCDT group who was found not to have a DVT was excluded from all
analyses. PTS developed over the 24-month period in 157 of 336 patients (47%) assigned to
the PCDT group and in 171 of 355 patients (48%) assigned to the control group (risk ratio,
0.96; 95% confidence interval (CI) 0.82 -1.11). [3 As the intervention had no significant
effect on the outcome, we addressed both arms of the study as one cohort.

Comparison of baseline characteristics of the SOX and ATTRACT cohorts
Compared to the SOX cohort, patients in the ATTRACT cohort were younger, had higher
BMI, and a greater proportion had unprovoked DVT. None had cancer associated DVT
(Table 1). Twenty five percent of patients in the ATTRACT cohort had previous DVT at
baseline compared to none in the SOX cohort. Most patients in the SOX and ATTRACT
trials were treated with low molecular weight heparin followed by a vitamin K antagonist.
Patients in the ATTRACT cohort received a longer median duration of anticoagulation.

Another important difference between the two cohorts was how the anatomical extent of
DVT was categorized. Both trials categorized patients according to the most proximal extent
of DVT. However, in the ATTRACT trial, DVT was categorized as iliofemoral or femoralpopliteal, whereas in the SOX trial DVT was categorized as iliac, common femoral, femoral
or popliteal. Unlike the SOX trial, the ATTRACT trial did not include patients with popliteal
DVT (i.e., without more proximal involvement). We were not able to divide ATTRACT
patients with iliofemoral DVT into those with only common femoral involvement and those
with iliac involvement.

Validation of the SOX-PTS score
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Table 2 shows results of the primary analysis, validation of the SOX-PTS score in the
ATTRACT trial cohort. The odds ratio for PTS for patients with a SOX-PTS score of 1 (vs 0)
in the ATTRACT cohort was 1.43 (95% CI 0.92 to 2.23), whereas in the SOX cohort it was
2.29 (1.27 to 4.11). The odds for PTS development increased to 4.52 (2.59 to 8.06) for
patients in the ATTRACT cohort who had a SOX –PTS score of ≥4 (vs. 0) compared to 5.90
(2.09 to 16.62) in the SOX cohort. Within the ATTRACT cohort, 69% of patients who had a
SOX-PTS score ≥4 developed PTS, vs. 42% of patients who had a score of 1 (Table 2).
When applied to the ATTRACT population, the SOX-PTS score achieved good
discrimination (c-statistic 0.63; 95% CI 0.59-0.67) and calibration (Figure 1).

Secondary analyses
Results of the secondary analysis using moderate-severe PTS (Villalta scale≥10) and severe
PTS (Villalta scale>14) as the outcomes are shown in Table 3 and Figure 1. The model’s
performance (discrimination and calibration) improved for both secondary outcomes (cstatistic 0.67; 95% CI 0.62 to 0.72 for moderate-severe PTS and 0.70; 0.64 to 0.77 for severe
PTS; Table 4).

Distributions of the SOX-PTS score in the SOX and ATTRACT cohorts for the primary and
secondary outcomes are shown in Table 5. The ATTRACT cohort had more patients
classified in the higher risk groups according to the SOX-PTS score (score 3 or higher).
Interestingly, distribution of the scores in the validation cohort was closest to the distribution
in the derivation cohort when considering moderate-severe PTS as the outcome, probably due
to the above mentioned differences in definition of the PTS outcome in the two studies (i.e.
Ginsberg criteria in SOX vs. Villalta criteria in ATTRACT).
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Sensitivity analyses after multiple imputation to replace missing Villalta scores in the
ATTRACT cohort
Results of the sensitivity analysis using multiple imputation for patients missing outcome
data are shown in Table 1S Supporting information. Multiple imputation was performed on
170 patients, of whom 80 patients missed all four preplanned outcome assessments visits and
90 patients missed one to three outcome assessment visits. Imputation yielded 95 additional
patients with PTS than the original dataset.

Distribution of the SOX-PTS score in the SOX trial cohort and imputed ATTRACT trial
datasets is shown in Table 2S Supporting information. Similarly to results in the non-imputed
dataset, distribution was closest to that of the derivation (SOX trial) cohort when considering
moderate to severe PTS as the outcome. Application of the SOX-PTS score on the imputed
ATTRACT dataset had little effect on the performance of the model (Table 3S of Supporting
information).

Exploratory analysis- Model updating
We tried to improve the SOX-PTS model's performance by updating our model.
Multivariable logistic analysis of the ATTRACT data (using the non-imputed original
dataset) suggested that advancing age is a predictor of PTS (Table 4S Supporting
information). Hence, we updated the model by adding age as an additional variable (Table
5S), categorized into three groups: <40, 40-64, ≥65 years. The updated model has possible
scores from 1 to 7. Table 6S Supporting information shows the distribution of the updated
SOX-PTS model in the ATTRACT Study cohort. We repeated secondary analyses with
moderate-severe PTS and severe PTS as the outcomes (Table 5S). For both the primary
analysis and the secondary analyses, performance of the updated model was very similar to
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the original score (for the primary analysis, outcome PTS, c-statistic 0.65; 95% CI 0.61 to
0.69, for the secondary analyses, outcome moderate-severe PTS, 0.68; 0.63 to 0.72 and
outcome severe PTS, 0.70; 0.64 to 0.76) (Table 7S). Calibration plots for the updated model
are presented in Figure 1S supporting information. Internal validation by the bootstrapping
technique for the updated model is shown in Table 8S Supporting information. Results show
good agreement with the observed estimates. Sensitivity analysis after multiple imputation
for patients with missing outcome data in the ATTRACT cohort was also performed for the
updated model (Tables 9S-11S Supporting information). As in the original model, multiple
imputation had little effect on the performance of the model.

Discussion
We externally validated the SOX-PTS score in an independent prospective cohort of patients
with proximal DVT. The model's performance was good, despite differences in
characteristics between the derivation and validation cohorts.

In terms of these differences, first, patients in the ATTRACT cohort might have had a higher
baseline risk for PTS (25% of the cohort had recurrent DVT, more patients were in the higher
BMI categories; both of these factors are known risk factors for PTS). [11, 12 Second, in the
ATTRACT trial, DVT was categorized into iliofemoral vs femoral-popliteal, whereas in the
SOX trial, most proximal extent of DVT was divided into four categories (iliac, common
femoral, femoral and popliteal), hence we were able to pick out iliac DVT, which proved to
be an important predictor of PTS. [2 Unfortunately, we did not have information on the
proportions of patients with iliac DVT in the ATTRACT cohort. Nevertheless, we chose not
to remove this predictor from the score, as we believe that other groups will try to validate the
SOX-PTS score in other populations (that hopefully will have information on the four
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categories of extent of DVT, like the SOX cohort did). If we removed this predictor, the
opportunity to look at the performance of what is considered to be an important predictor of
PTS, in other populations, would have been lost. Third, outcome definition was also different
between the two cohorts: in the derivation cohort (SOX cohort), Ginsberg's criteria were used
to define PTS, whereas in the validation cohort (ATTRACT cohort), the Villalta scale was
used. Ginsberg-defined PTS captures more severe PTS than Villalta-defined PTS. [9 To
overcome this issue, we preplanned a secondary analysis looking at moderate-severe and
severe PTS according to the Villalta scale as the outcomes in the ATTRACT cohort. Indeed,
the model's performance was better when these secondary outcomes were considered.

One additional difference between the derivation and validation cohorts should be
considered. The experimental interventions that the study participants in the two cohorts
received were different (active elastic compression stockings in the SOX trial and PCDT in
the ATTRACT trial) and might have modified the likelihood of developing PTS. However,
during ATTRACT trial follow up, there was no significant between-group difference in the
percentage of patients who developed PTS (47% in the PCDT group and 48% in the control
group; risk ratio, 0.96; 95% CI, 0.82 to 1.11). Therefore, we analyzed both arms of the study
as one combined cohort. We also accounted for this fact by including assigned treatment arm
as a parameter in the multivariable analysis, and it did not influence the final model.

To the best of our knowledge, only two other prediction models for PTS have been published.
[13, 14 The model by Amin and colleagues is [13 a two-step model consisting of a first
model to be applied at baseline to predict the probability of developing PTS at 6 months, and
a second model to be applied at 6 months to predict the probability of PTS at 24 months for
those patients who had not developed PTS by 6 months. Predictor variables in the first step
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were: age>56, BMI>30, male sex, varicose veins, history of venous thrombosis, smoking
status, provoked DVT and iliofemoral DVT. Predictor variables in the second step were the
same as in the first step with the addition of residual vein obstruction. The model by Méan
and colleagues [14 includes age > 75years, prior varicose vein surgery, multi-level
thrombosis, concomitant use of antiplatelet/ non-steroidal anti-inflammatory drugs, and
number of leg symptoms and signs. We could not validate these two prediction models in the
ATTRACT cohort because of lack of data on some predictor variables (smoking status,
varicose veins and residual obstruction for the prediction model by Amin et al [13, and prior
varicose vein surgery for the prediction model by Méan et al [14). However, the three
models are in agreement regarding some of the predictor variables (e.g., age, iliofemoral
involvement in DVT, severe symptoms and signs at DVT diagnosis). A comparative
validation study evaluating the performance of different PTS prediction models on the same
data set would generate additional important information.

The present study has potential limitations. In addition to differences between the two cohorts
as elaborated above, this validation cohort (like the derivation cohort) is based on data from a
randomized trial and not a prospective cohort study designed specifically for this purpose.
However, we controlled for this by including the treatment arm as a parameter in the
multivariable analysis, and it did not influence the final model. Also, as most patients in the
SOX and ATTRACT trials were treated with low molecular heparin followed by warfarin,
the validity of this model in patients treated with the newer direct oral anticoagulants should
be addressed.

In conclusion, we externally validated the SOX-PTS score for estimating the risk of
developing PTS, moderate to severe PTS, and severe PTS, in patients with proximal DVT.
13

All items in the model are readily available at the time of DVT diagnosis and thus the score
may be useful to estimate the risk of developing PTS at the time of DVT diagnosis. Further
external validation in different patient cohorts is required.
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Table 1: Baseline Characteristics of the SOX trial and ATTRACT trial participants
Characteristics
Sex - female: n (%)
Age Category (years): n (%)
< 40
40-64
≥ 65
Ethnicity: n (%)
Caucasian
Other
Iliac DVT - yes: n (%)
Common femoral vein or Iliac vein DVT yes: n (%)
Baseline Villalta Score category
0-4 (none)
5-9 (mild)
10-14 (moderate)
>14 (severe)
Unknown
DVT Type: n (%)
Cancer associated
Secondary Risk Factors
Unprovoked
Side of DVT: n (%)
Left
Right
Previous DVT or PE: n (%)
BMI category (kg/m2): n (%)
< 25
25-34
≥ 35
Unknown
Duration of anticoagulation (days): median
(Q1, Q3)

SOX
n = 762
305 (40)

ATTRACT
n = 691
265 (38)

129 (17)
423 (56)
210 (28)

152 (22)
418 (60)
121 (18)

688 (90)
74 (10)
90 (12)

542 (78)
149 (22)
NA

NA

NA

391 (57)

NA

164 (22)
298 (39)
216 (28)
84 (11)
0

126 (18)
239 (35)
192 (18)
132 (19)
2 (<1)

p-value
0.51
< 0.001

< 0.001

0.002

< 0.001
79 (10)
206 (27)
477 (63)

0
101 (15)
590 (85)
0.018

422 (55)
340 (45)
0

425 (62)
266 (38)
170 (25)

193 (25)
457 (60)
112 (15)
0

115 (17)
388 (57)
184 (27)
4 (1)

185 (111-233)

223 (186, 372)

< 0.001
< 0.001

< 0.001*

PTS; post thrombotic syndrome, DVT; deep vein thrombosis, BMI; body mass index
* Non-parametric Wilcoxon rank sum test
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Table 2: Performance of SOX-PTS score in SOX Trial (derivation set) and ATTRACT
Trial (validation set) data

SOX Study
(N = 762)
Variable

Events/n
(%)

ATTRACT Study
(N = 691)

OR
(95% CI)

Events/n
(%)

1.96
(1.08 to 3.57)
2.17
(1.27 to 3.72)

More extensive (vs less extensive)
DVT*, 1 point
BMI ≥ 35 (vs < 35), 2 points

OR
(95% CI)
1.14
(0.83 to 1.55)
1.94
(1.37 to 2.78)

Baseline Villalta score category#
(vs None to Mild)
2.64
(1.41 to 4.96)
2.00
(1.21 to 3.29)

Severe, 2 points
Moderate, 1 point

n/a

None to Mild

86/132 (65)
98/192 (51)

2.60
(1.71 to 4.00)
1.49
(1.04 to 2.14)

144/367 (39)

n/a

SOX-PTS Score (vs 0)
≥4

6/21 (29)

3

14/56 (25)

2

20/122 (16)

1

27/201 (13)

0

23/362 ( 6)

5.90
(2.09 to 16.62)
4.91
(2.35 to 10.27)
2.89
(1.53 to 5.47)
2.29
(1.27 to 4.11)
n/a

61/88 (69)
74/120 (62)
61/136 (45)
82/197 (42)

4.52
(2.59 to 8.06)
3.22
(1.96 to 5.34)
1.63
(1.01 to 2.63)
1.43
(0.92 to 2.23)

50/150 (33)

n/a

PTS; post thrombotic syndrome, DVT; deep vein thrombosis, BMI; body mass index OR; odds ratio.
*Iliac vs non iliac vein involvement in the SOX trial; Common femoral and/or iliac vein vs femoral-popliteal
vein involvement in the ATTRACT trial
#

Villalta score categories: None, score of 0-4; Mild, 5-9; Moderate, 10-14; Severe, >14
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Table 3: Secondary analyses: Performance of SOX-PTS score using moderate-severe
PTS and severe PTS as the outcomes

Category
More extensive (vs. less
extensive) DVT*
BMI ≥ 35 (vs < 35)

ATTRACT
Moderate to Severe PTS
OR for PTS
(95% CI)
1.25
(0.84 to 1.87)
1.61
(1.07 to 2.41)

ATTRACT
Severe PTS
OR for PTS
(95% CI)
1.31
(0.76 to 2.26)
2.03
(1.20 to 3.43)

4.19
(2.61 to 6.77)
2.16
(1.36 to 3.42)

4.59
(2.48 to 8.51)
1.70
(0.88 to 3.30)

6.72
(4.42 to 13.86)
4.33
(2.26 to 8.74)
2.30
(1.16 to 4.72)
1.81
(0.94 to 3.65)

12.17
(4.03 to 36.71)
6.87
(2.27 to 20.79)
3.53
(1.11 to 11.23)
2.58
(0.82 to 8.08)

Baseline Villalta score category#
(vs None to Mild)
Severe
Moderate
SOX-PTS Score (vs 0)
≥4
3
2
1

PTS; post thrombotic syndrome, DVT; deep vein thrombosis, BMI; body mass index OR; odds ratio
*Iliac vs non iliac vein involvement in the SOX trial; Common femoral and/or iliac vein vs femoral-popliteal
vein involvement in the ATTRACT trial
#

Villalta score categories: None, score of 0-4; Mild, 5-9; Moderate, 10-14; Severe, >14
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Table 4: Model Fit Statistics and Association of Predicted Probability and Observed Response for the primary outcome and secondary
outcomes
Model Fit
Statistics

% Concordant*
% Discordant
% Tied
Somers’ D
Gamma
Tau-a
c-statistic
(95%CI)

PTS
based on
baseline
variables
58.0
30.0
12.0
0.28
0.32
0.14
0.64
(0.60 to 0.68)

based on
SOX-PTS
score
53.1
26.7
20.2
0.27
0.33
0.13
0.63
(0.59 to 0.67)

Moderate- Severe
PTS
based on
based on
baseline
SOX-PTS
variables
score
63.6
57.3
26.6
23.8
9.8
18.9
0.37
0.34
0.41
0.41
0.12
0.11
0.69
0.67
(0.64 to 0.73) (0.62 to 0.72)

Severe PTS
based on
baseline
variables
67.3
23.9
8.8
0.43
0.48
0.08
0.72
(0.65 to 0.78)

based on
SOX-PTS
score
61.4
20.6
18.0
0.41
0.50
0.07
0.70
(0.64 to 0.77)

*To evaluate concordance, all possible pairs of patients (i.e. one patient has a PTS event and the other has no PTS event) are assessed. For a pair of patients, the actual
outcome (i.e. PTS) and the predicted probability of outcome from the logistic model can have 3 types of results:
1) Concordant: in the pair, the patient with higher predicted probability had PTS event
2) Discordant: in the pair, the patient with lower predicted probability had PTS event
3) Both patients in the pair have the same predicted probability (Tie condition)
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Table 5: Distribution of the SOX-PTS Score in the SOX and ATTRACT Studies

SOX-PTS
Score
0
1
2
3
4
5

SOX
(N = 762)
PTS*
N (%)
23/362 ( 6)
27/201 (13)
20/122 (16)
14/56 (25)
6/20 (30)
0/1

PTS#
N (%)
50/150 (33)
82/197 (42)
61/136 (45)
74/120 (62)
38/54 (70)
23/34 (68)

ATTRACT
(N = 691)
Moderate-Severe
PTS# N (%)
14/150 ( 9)
31/197 (16)
26/136 (19)
37/120 (31)
22/54 (41)
14/34 (41)

Severe PTS#
N (%)
4/150 ( 3)
13/197 ( 7)
12/136 ( 9)
19/120 (16)
14/54 (26)
8/34 (24)

PTS; post thrombotic syndrome
* PTS was defined according to the Ginsberg criteria
# PTS was defined according to Villalta score categories: None, score of 0-4; Mild, 5-9; Moderate, 10-14;
Severe, >14
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Figure 1. Calibration plots for the SOX-PTS score applied to the ATTRACT cohort
A.

PTS as outcome

B.

Moderate-severe PTS as outcome

C.

Severe PTS as outcome
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Supporting materials for “External validation of the SOX-PTS score (clinical prediction
model for the post-thrombotic syndrome) in a prospective multicenter trial of patients with
proximal deep vein thrombosis”

ATTRACT Clinical Centers
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Albert Einstein Medical Center
Allegheny General Hospital
Ann Arbor VA Health Center
Baptist Cardiac and Vascular Institute
Central DuPage Hospital
Christiana Care Hospital
Cleveland Clinic Foundation
Danbury Hospital
Eastern Connecticut Hematology & Oncology Associates
Florida Hospital
Forsyth Medical Center
Gundersen Clinic, Ltd
Georgetown University
Henry Ford Health System
Holy Name Medical Center
Jobst Vascular Center
Maine Medical Center
Massachusetts General Hospital
Mayo Clinic
Mease Countyside Hospital
Medical College of Wisconsin/Froedtert Hospital & Clinics
Medical University of South Carolina
Oregon Health & Science University
Pepin Heart Hospital and Dr. Kiran C. Patel Research Institute
Phoenix Heart & Cardiovascular
Riverside Methodist Hospital
Rhode Island Hospital
Providence Sacred Heart Medical Center & Children’s Hospital
Southern Illinois University
St. Elizabeth Regional Medical Center (NE)
St. Joseph Hospital
St. Luke’s Hospital and Health Network
St. Luke’s Hospital: Brandt Wible
St. Vincent Medical Group
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Stanford University Medical Center
Staten Island University Hospital
Temple University Hospital
The Reading Hospital
TriHealth/Good Samaritan Hospital
University of Iowa
University of Illinois- Chicago
University of Maryland
University of Michigan Hospitals and Health Centers
University of Minnesota
University of New Mexico
University of North Carolina
University of Pittsburgh
University of Utah Medical Center
University of Virginia Health System
Utah Valley Reginal Medical Center
Weill Cornell Medical College
Western Penn Allegheny Health System
Washington University in St. Louis
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Table 1S: Performance of SOX-PTS score using the ATTRACT Data after Multiple
Imputation

OR for PTS
(95% CI)
1.15
(0.80 to 1.66)
1.77
(1.13 to 2.77)

Moderate to
Severe PTS
OR for PTS
(95% CI)
1.19
(0.81 to 1.73)
1.35
(0.89 to 2.05)

OR for PTS
(95% CI)
1.30
(0.77 to 2.21)
1.65
(1.00 to 2.74)

1.78
(1.17 to 2.71)

5.06
(2.93 to 8.73)

5.72
(2.96 to 11.05)

3.78
(2.17 to 6.59)

2.22
(1.41 to 3.52)

2.00
(1.02 to 3.91)

PTS
Category
More extensive DVT*(vs less
extensive)
BMI ≥ 35 (vs < 35)
Baseline Villalta score category#
(vs None to Mild)
Severe
Moderate

Severe PTS

SOX-PTS Score (vs 0)
5.54
6.01
10.38
(2.74 to 11.18)
(2.85 to 12.65)
(3.29 to 32.76)
3.33
4.15
6.09
3
(1.86 to 5.96)
(2.11 to 8.18)
(1.97 to 18.79)
1.74
2.38
3.30
2
(1.04 to 2.91)
(1.18 to 4.78)
(1.03 to 10.56)
1.48
1.92
2.42
1
(0.92 to 2.36)
(1.01 to 3.63)
(0.79 to 7.43)
Note: ATTRACT results are based on 20 multiple imputation datasets
PTS; post thrombotic syndrome, DVT; deep vein thrombosis, BMI; body mass index OR; odds
ratio.
* Iliac vs non iliac vein involvement in the SOX trial; Common femoral and/or iliac vein vs
femoral-popliteal vein involvement in the ATTRACT trial
#Villalta score categories: None, score of 0-4; Mild, 5-9; Moderate, 10-14; Severe, >14
≥4
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Table 2S: Distribution of the SOX-PTS Score in the SOX trial cohort and imputed
ATTRACT trial Datasets
SOX*
ATTRACT, multiple imputation
(N = 762)
(N = 691)
SOX-PTS
PTS#
Moderate-Severe#
Severe PTS#
PTS
Score
N (%)
N (%)
PTS N (%)
N (%)
23/362
(
6)
69.4/150
(45)
22.5/150
(15)
7.9/150
( 5)
0
27/201 (13)
110.3/197 (56)
49.5/197 (25)
22.4/197 (11)
1
20/122 (16)
81.5 /136 (60)
40.0/136 (29)
20.3/136 (15)
2
14/56 (25)
89/120 (74)
50.5/120 (42)
29.2/120 (24)
3
6/20 (30)
41.6/54 (77)
24.1/54 (45)
17.3/54 (32)
4
0/1
31.2/34 (92)
21.0/34 (62)
13.8/34 (41)
5
PTS; post thrombotic syndrome
* PTS was defined according to the Ginsberg criteria
# PTS was defined according to Villalta score categories: None, score of 0-4; Mild, 5-9;
Moderate, 10-14; Severe, >14
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Table 3S: Model fit statistics of the SOX-PTS Score in the imputed ATTRACT trial cohort
Model Fit
Statistics
% Concordant
% Discordant
% Tied
Somers’ D
Gamma
Tau-a
C statistic (95% CI)

PTS as Outcome
53.5 (50.9 to 55.5 )
25.8 (24.1 to 28.1)
20.7 (20.4 to 21.0)
0.28 (0.23 to 0.31)
0.35 (0.29 to 0.39)
0.13 (0.11 to 0.15)
0.64 (0.61 to 0.66)

Moderate-Severe
PTS as Outcome
55.8 (52.8 to 59.8)
24.9 (21.6 to 27.4)
19.4 (18.6 to 19.9)
0.31 (0.25 to 0.38)
0.38 (0.32 to 0.47)
0.13 (0.11 to 0.16)
0.65 (0.63 to 0.69)

Severe PTS as
Outcome
60.0 (55.7 to 64.2)
21.7 (18.3 to 25.3)
18.3 (17.5 to 19.0)
0.38 (0.30 to 0.46)
0.47 (0.37 to 0.56)
0.10 (0.09 to 0.13)
0.69 (0.65 to 0.73)
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Table 4S: Multivariable logistic regression model of the association between ATTRACT
population baseline characteristics and PTS development
Baseline Variables
OR (95% CI)
P-value
Treatment arm (PCDT vs. No PCDT)
0.91 (0.65, 1.27)
0.57
Iliofemoral vs. Popliteal DVT
1.17 (0.82, 1.68)
0.39
Clinical Centre
0.0008
Age (per year)
1.03 (1.01, 1.04) <0.0001
Sex (Female vs. Male)
0.70 (0.49, 1.01)
0.060
BMI, kg/m2 (per unit increase)
1.05 (1.02, 1.07)
0.0003
DVT Symptom Duration (per day)
1.04 (1.00, 1.09)
0.064
Ipsilateral DVT (No vs. Yes)
1.02 (0.19, 5.51)
0.77
Contralateral DVT (No vs. Yes)
1.06 (0.49, 2.31)
0.17
Inpatient (No vs. Yes)
1.06 (0.65, 1.75)
0.81
Baseline Villalta Score (per point increase)
1.13 (1.09, 1.17) <0.0001
PTS; post thrombotic syndrome, DVT; deep vein thrombosis, BMI; body mass index
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Table 5S: Updated SOX-PTS score including age as an additional variable applied to the
ATTRACT cohort
Parameter

PTS

Moderate-Severe PTS

Severe PTS

OR (95%CI)

OR (95%CI)

OR (95%CI)

1.17 (0.85 to 1.61)

1.30 (0.87 to 1.95)

1.36 (0.78 to 2.36)

1

2.03 (1.42 to 2.91)

1.67 (1.10 to 2.53)

2.04 (1.20 to 3.47)

2

Severe

2.66 (1.73 to 4.11)

4.11 (2.52 to 6.71)

4.34 (2.32 to 8.13)

2

Moderate

1.59 (1.10 to 2.30)

2.26 (1.42 to 3.59)

1.71 (0.88 to3.32)

1

≥ 65

2.37 (1.42 to 3.95)

2.20 (1.11 to 4.37)

1.28 (0.48 to 3.40)

2

40-64

1.90 (1.27 to 2.83)

2.23 (1.30 to 3.83)

1.83 (0.91 to 3.69)

1

-0.73 (-1.02 to- 0.43)

-2.90 ( -3.53 to -2.27)

-3.63 (-4.48 to -2.78)

≥6

13.22 (3.76 to 46.53)

6.86 (1.71 to 27.58)

10.02 (3.01 to 33.29)

5

9.93 (3.27 to 30.11)

5.56 (1.51 to 20.47)

6.47 (2.14 to 19.53)

4

7.47 (2.63 to 21.24)

3.99 (1.13 to 14.14)

7.20 (2.62 to 19.80)

3

4.66 (1.69 to12.88)

2.00 (0.57 to 7.07)

2.86 (1.00 to 8.15)

2

2.78 (1.01 to 7.64)

1.43 (0.41 to 5.06)

1.76 (0.60 to5.18)

1

2.63 (0.93 to7.40)

0.83 (0.22 to 3.21)

NA§

More extensive (vs less
extensive) DVT*
BMI ≥ 35 (vs < 35)

Points

Baseline Villalta score
category# (vs None to
Mild)

Age Category (vs < 40)

Intercept
Updated SOX-PTS
score (vs 0)

PTS; post thrombotic syndrome, DVT; deep vein thrombosis, BMI; body mass index OR; odds ratio
*Iliac vs non iliac vein involvement in the SOX trial; Common femoral and/or iliac vein vs femoralpopliteal vein involvement in the ATTRACT trial
#Villalta score categories: None, score of 0-4; Mild, 5-9; Moderate, 10-14; Severe, >14
§ Quasi-complete separation data, score categories 0 and 1 are combined as reference level
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Table 6S: Distribution of the updated* SOX-PTS score in the ATTRACT Study cohort

Updated SOXPTS score
0
1
2
3
4
5
6
7

PTS
N (%)
5/28 (18)
44/121 (36)
72/191 (38)
78/155 (50)
65/105 (62)
41/60 (68)
21/29 (72)
2/2 (100)

ATTRACT cohort
(N = 691)
Moderate-Severe PTS
N (%)
3/28 (11)
11/121 (9)
28/191 (15)
30/155 (19)
34/105 (32)
24/60 (40)
12/29 (41)
2/2 (100)

Severe PTS
N (%)
0/28 (0)
5/121 (4)
11/191 (6)
14/155 (9)
21/105 (20)
11/60 (18)
7/29 (24)
1/2 (50)

*Updated model includes age as an additional variable
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Table 7S: Model Fit Statistics and Association of Predicted Probability and Observed
Response, updated* SOX-PTS Score

Model Fit
Statistics

PTS
as outcome
based on
based on
baseline
SOX-PTS
variables
score

Moderate- severe
PTS as outcome
based on
based on
baseline
SOX-PTS
variables
score

Severe PTS
as outcome
based on
based on
baseline
SOX-PTS
variables
score*

70.2
61.7
%Concordant
63.3
55.8
66.3
59.3
25.6
21.8
31.5
26.0
27.7
24.1
%Discordant
4.2
16.5
5.2
18.2
6.0
16.7
% Tied
0.45
0.40
0.32
0.30
0.39
0.35
Somers’ D
0.47
0.48
0.34
0.37
0.41
0.42
Gamma
0.08
0.07
0.16
0.15
0.13
0.12
Tau-a
0.73
0.70
C statistic
0.66
0.65
0.70
0.68
(0.66
to
0.79)
(0.64
to 0.76)
(0.62 to 0.70) (0.61 to 0.69) (0.65 to 0.75) (0.63 to 0.72)
(95% CI)
*Updated model includes age as an additional variable
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Table 8S: Internal Validation with Bootstrapping Technique of updated* SOX-PTS scoreOdds Ratio estimates (95% CL)
Updated
SOXPTS
Score
(vs 0)
≥6

ATTRACT
PTS

Moderate-Severe PTS

Severe PTS§

Raw
13.22
(3.76 to
6.53)

Boot#
14.62
(4.68 to
65.00)

Raw
6.86
(1.71 to
27.58)

Boot#
7.07
(1.91 to
30.00)

Raw
10.02
(3.01 to
33.29)

Boot#
9.95
(3.01 to
54.50)

5

9.93
(3.27 to
30.11)

10.40
(3.90 to
42.40)

5.56
(1.51 to
20.47)

5.82
(1.84 to
23.76)

6.47
(2.14 to
19.53)

6.55
(2.11 to
32.68)

4

7.47
(2.63 to
21.24)

7.50
(3.13 to
28.36)

3.99
(1.13 to
14.14)

4.07
(1.34 to
15.87)

7.20
(2.62 to
19.80)

7.11
(2.96 to
37.73)

3

4.66
(1.69 to
12.88)

4.74
(1.95 to
18.68)

2.00
(0.57 to
7.07)

2.06
(0.69 to
7.63)

2.86
(1.00 to
8.15)

2.89
(1.01 to
14.79)

2

2.78
(1.01 to
7.64)

2.87
(1.18 to
11.14)

1.43
(0.41 to
5.06)

1.46
(0.48 to
5.32)

1.76
(0.60 to
5.18)

1.75
(0.60 to
9.87)

1

2.63
(0.93 to
7.40)

2.67
(1.05 to
10.26)

0.83
(0.22 to
3.21)

0.85
(0.23 to
3.38)

C Statistics for Bootstrap Samples, Updated SOX-PTS Score
Data
C-Statistics (95% CI)
ATTRACT – PTS (Continuous)
0.65 (0.61 to 0.69)
ATTRACT – Moderate-Severe PTS (Continuous)
0.68 (0.63 to 0.73)
ATTRACT – Severe PTS (Continuous)
0.70 (0.64 to 0.76)
ATTRACT – PTS (Categorical)
0.64 (0.60 to 0.68)
ATTRACT – Moderate-Severe PTS (Categorical)
0.66 (0.62 to 0.71)
ATTRACT – Severe PTS (Categorical)
0.68 (0.62 to 0.74)
*Updated model includes age as an additional variable
#Boot = bootstrap estimate;
§ Reference level is score 0 and 1
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Table 9S: Final Models for the Updated* SOX-PTS Score using ATTRACT Data, after
Multiple Imputation

OR for PTS
(95% CI)
1.19
(0.82 to 1.72)
1.82
(1.15 to 2.86)

Moderate to
Severe PTS
OR for PTS
(95% CI)
1.23
(0.84 to 1.79)
1.36
(0.89 to 2.08)

OR for PTS
(95% CI)
1.34
(0.78 to 2.29)
1.67
(1.00 to 2.79)

3.82
(2.17 to 6.71)
1.85
(1.21 to 2.83)

4.88
(2.81 to 8.50)
2.25
(1.41 to 3.59)

5.41
(2.80 to 10.45)
1.99
(1.01 to 3.93)

1.67
(0.94 to 2.96)

1.24
(0.63 to 2.45)

0.91
(0.35 to 2.33)

1.54
(0.98 to 2.40)

1.52
(0.90 to 2.58)

1.31
(0.62 to 2.75)

PTS
Category
More extensive (vs less extensive)
DVT*
BMI ≥ 35 (vs < 35)

Severe PTS

Age (vs. < 40)
≥ 65
40-64
Baseline Villalta score category#
(vs None to Mild)
Severe

Moderate
SOX-PTS Score (vs 0)

12.74
6.44
(2.42 to 67.00)
(1.40 to 29.73)
5.56
4.52
5
(1.71 to 18.05)
(1.07 to 19.00)
4.22
3.55
4
(1.35 to 13.13)
(0.91 to 13.81)
2.43
1.91
3
(0.84 to 7.02)
(0.47 to 7.78)
1.53
1.51
2
(0.55 to 4.24)
(0.40 to 5.68)
1.37
0.94
1
(0.47 to 4.01)
(0.24 to 3.64)
Note: ATTRACT results are based on 20 multiple imputation datasets
*Updated model includes age as an additional variable
# Quasi-complete separation data, score 0 and 1 are combined as reference level
≥6

Quasi-complete
Data#
7.71
(2.21 to 26.90)
5.35
(1.87 to 15.32)
5.62
(2.04 to 15.52)
2.47
(0.89 to 6.87)
1.55
(0.59 to 4.04)
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Table 10S: Distribution of the updated* SOX-PTS Score in the imputed ATTRACT
Datasets

New Score
PTS / N (%)
0
1
2
3
4
5
6
7

11.7/28 (42)
59.5/121 (49)
99.3/191 (52)
98.1/155 (63)
78.6/105 (75)
47.8/60 (80)
25.9/29 (89)
2/2 (100)

ATTRACT cohort
(N = 691)
Moderate-Severe PTS
/ N (%)
5.1/28 (18)
20.1/121 (17)
46/191 (24)
44.4/155 (29)
44.9/105 (43)
29.2/60 (49)
15.8/29 (54)
2/2 (100)

Severe PTS / N (%)
0.9/28 (3)
9.4/121 (8)
19.3/191 (10)
23.4/155 (15)
30.2/105 (29)
16.7/60 (28)
10.1/29 (35)
1/2 (50)

Note: ATTRACT results are based on 20 multiple imputation datasets
*Updated model includes age as an additional variable
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Table 11S: Model Fit Statistics for updated* SOX-PTS Score, after multiple imputation
Model Fit Statistics

PTS
Mean
Min, Max
55.1
50.8, 57.8
25.7
20.6, 28.5
19.2
18.4, 28.6
0.29
0.24, 0.34
0.36
0.30, 0.42
0.14
0.11, 0.16
0.65 (0.60 to 0.69)

Moderate-Severe PTS
Mean
Min, Max
56.2
53.2, 59.9
26.0
23.1, 28.5
17.8
16.9, 19.7
0.30
0.25, 0.37
0.37
0.30, 0.44
0.13
0.11, 0.15
0.65 (0.59 to 0.70)

%Concordant
%Discordant
% Tied
Somers’ D
Gamma
Tau-a
c-statistic (95%CI)
continuous
0.65 (0.60 to 0.69)
0.65 (0.60 to 0.70)
c-statistic (95%CI)
categorical
*Updated model includes age as an additional variable

Severe PTS
Mean
Min, Max
59.5
55.5, 65.0
23.3
19.0, 26.7
17.2
16.0, 19.3
0.36
0.29, 0.46
0.44
0.35, 0.55
0.10
0.08, 0.12
0.68 (0.61 to 0.74)
0.68 (0.61 to 0.75)
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Figure 1S. Calibration plots for updated* SOX-PTS score applied to the ATTRACT cohort
A.

PTS as outcome

B.

Moderate- severe PTS as outcome

C.

Severe PTS as outcome

*Updated model includes age as an additional variable
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